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Highlights 4 
 We have designed an epitope ensemble vaccine for malaria. 
 We have extended previous methodology to include heteroclitic peptides in our 
epitope ensemble vaccine formulation. 
 We have estimated the level of population protection afforded by such an ensemble 
vaccine 
 We have promulgated a putative global malaria vaccine and ones specific to endemic 
regions of sub-Saharan Africa.   
 
Abstract 
Malaria is a global health burden, and a major cause of mortality and morbidity in Africa. Here 
we designed a putative malaria epitope ensemble vaccine by selecting an optimal set of 
pathogen epitopes. From the IEDB database, 584 experimentally-verified CD8+ epitopes and 
483 experimentally-verified CD4+ epitopes were collected; 89% of which were found in 8 
proteins. Using the PVS server, highly conserved epitopes were identified from variability 
analysis of multiple alignments of Plasmodium falciparum protein sequences. The allele-
dependent binding of epitopes was then assessed using IEDB analysis tools, from which the 
population protection coverage of single and combined epitopes was estimated. Ten 
conserved epitopes from four well-studied antigens were found to have a coverage of 97.9% 
of the world population:  7 CD8+ T cell epitopes (LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, 
TPYAGEPAPF, LLACAGLAY, SLKKNSRSL, and NEVVVKEEY) and 3 CD4+ T cell epitopes 
(MRKLAILSVSSFLFV, KSKYKLATSVLAGLL and GLAYKFVVPGAATPYE). The addition of four 
heteroclitic peptides - single point mutated epitopes - increased HLA binding affinity and 
raised the predicted world population coverage above 99%. 
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1 INTRODUCTION  
 
Malaria is a mosquito-borne parasitic tropical disease. Ninety-one countries have continuing 
malaria transmission, with 212 million cases and 429,000 deaths in 2015. Over 92% of malaria 
cases occur in Africa and over 75% of malaria deaths in 13 countries within sub-Saharan Africa 
(WHO, 2016). Plasmodium falciparum is the principal malaria parasite in Africa. It has a three-
stage lifecycle: exo-erythrocytic and erythrocytic stages in humans and a sporogonic cycle in 
mosquitoes. The female anopheline mosquito initiates infection by inoculating sporozoites 
during a blood meal. These sporozoites invade hepatocytes, resulting in production and 
release of merozoites, which then invade red blood cells. In non-immune adults, clinical 
symptoms of malaria typically appear 10-15 days after an infective mosquito bite. Symptoms 
range from mild fever to anaemia, impaired consciousness, severe respiratory distress, and 
death.  
Individuals from endemic areas acquire a natural but incomplete protective immunity to P. 
falciparum. Cellular adaptive immunity is key to the response to P. falciparum. The CD8+ T 
cell-immunity has a role in the exoerythrocytic stage and in regulating immunosuppression 
during acute malaria (Tsuji, 2010). The transfer of CD8+ T cells clones into naïve mice confers 
protective immunity, while mice depleted of CD8+ T cells do not acquire protective immunity 
against malaria. Human CD8+ T cell responses have been detected against several P. 
falciparum proteins, including liver stage antigens. CD4+ T cell responses are needed to 
control parasite replication, yet cannot clear parasites from the blood. CD4+ T helper 1 cells 
(Th1) expressing IFN-γ play a role in acute infection, whereas antibody-helper T cells help 
prevent parasitaemia in the chronic phase (Perez-Mazliah and Langhorne, 2014). 
Malaria eradication faces many challenges, such as the emerging resistance of P. falciparum 
to artemisinin and other anti-malarial drugs, resistance of anopheline mosquitoes to 
insecticides, the absence of treatment and prevention programs in many areas, and reduced 
global anti-malaria funding. Thus there remains a pressing need to develop effective vaccines, 
the most cost-effective public health intervention for infectious disease. The first successful 
human malaria vaccine consists of live, radiation-attenuated P. falciparum sporozoites 
(PfSPZ), which confers protective immunity by inducing a CD8+ T cell response (Epstein et al., 
2011; Weiss and Jiang, 2012). Despite such promise, live attenuated vaccines challenges (e.g. 
sterile manufacturing, extreme cold-chain requirements, and safety concerns) have 
prompted the development of subunit vaccines. 
Current malaria subunit vaccines either target the parasite at the pre-erythrocytic stage or 
the asexual blood stage, or they act to block transmission. The selection of appropriate 
antigens as vaccine subunits is key to treating the different parasite stages. Vaccines targeting 
antigens expressed by gametes and zygotes, such as Pfs48/45, Pfs28, and Pfs25, may block 
transmission (Li et al., 2016) at the sexual and sporogonic stages.  Although this would not 
prevent clinical disease, it may slow infection rates (Birkett et al., 2013). Pre-erythrocytic 
vaccines aim to prevent sporozoites entering the liver and developing into infective 
merozoites, targeting sporozoites’ apical membrane antigens. However, such vaccines have 
failed to show significant efficacy against clinical malaria (Thera et al., 2011). Variant surface 
antigens expressed on the infected erythrocyte such as P. falciparum erythrocyte membrane 
protein 1 (PfEMP1) elicit an immune response in humans, but high antigenic diversity may 
diminish vaccine efficacy (Barry and Arnott, 2014).  Thus the highly conserved regions of 
Plasmodium antigens must be targeted.  
Here, we designed a putative peptide-based vaccine against malaria, comprising a small set 
of highly conserved epitopes of experimentally verified immunogenicity, which provide a 
wide population coverage. Our recent work has exemplified this approach against viruses: 
Hepatitis C (Molero-Abraham et al., 2013) and influenza (Sheikh et al., 2016). Since P. 
falciparum is likely to exhibit non-negligible allelic diversity in its antigenic proteins, we also 
considered epitope variants by introducing point mutations into the amino acid sequences of 
our selected epitopes. Such variants are commonly referred to as heteroclitic peptides, and 
increase MHC binding relative to the unsubstituted peptide, thereby potentiating intrinsic 
immunogenicity by acting as self-adjuvants (Adegoke et al., 2015; Adegoke and Grant, 2015)  
 
 
2 METHODS 
 
2.1 Collection of CD8+ and CD4+ T cell epitopes 
P. falciparum epitopes recognised by the T cell-mediated immune response were obtained 
from the Immune Epitope Database (IEDB), accessible at URL: http://www.iedb.org (Vita et 
al., 2015). The search was restricted to positive T cell assays in humans. 
 
2.2 Retrieval, clustering, and multiple sequence alignment generation for P. falciparum 
antigens 
The complete sequence of each protein containing at least one downloaded epitope (termed 
antigen hereafter) was retrieved from the Universal Protein Resource, URL:   
http://www.uniprot.org/uniprot/. Each retrieved antigen was BLASTed against the non-
redundant (NR) protein sequence database at the National Centre for Biotechnology 
information (NCBI), URL: https://blast.ncbi.nlm.nih.gov/Blast.cgi. Ten variant sequences 
corresponding to each identified P. falciparum antigen were selected. For the 8 antigens with 
the most epitopes a larger set containing more sequences was collected, and then clustered 
using CD-HIT (Fu et al., 2012), URL: http://weizhongli-lab.org/cdhit_suit. Sequences were 
clustered at identity thresholds of 90% and 98%. The two sets - highly homologous and CD-
HIT clustered sequences - were submitted to the MUSCLE server 
http://www.ebi.ac.uk/Tools/msa/muscle/ (Edgar, 2004) to create multiple sequence 
alignments (MSA). 
 
2.3 Calculating sequence variability of P. falciparum polyproteins  
To identify conserved epitopes, we first analysed each MSAs using the Protein Variability 
Server (PVS), URL: http://imed.med.ucm.es/PVS/ (Garcia-Boronat et al., 2008), to separate 
conserved consensus sequences from sequences exhibiting variability (aligned positions with 
Shannon Entropy, H, above 0.5).  Subsequently, conserved epitopes were identified as those 
epitopes falling within non-variable regions. 
 
 
 
2.4 Estimation of MHC class I and class II binding 
Affinities of conserved CD8+ T cell epitopes were predicted using the IEDB MHC-I binding 
prediction tool (http://tools.iedb.org/mhci/)(Kim et al., 2012). Epitopes with percentile rank 
of one or less for a given allele were considered to bind. Similarly, conserved CD4+ T cell 
epitopes were processed with the IEDB MHC-II binding prediction tool 
(http://tools.iedb.org/mhcii/), using the consensus method. Alleles in the top 10 percentile 
rank were considered to bind. This yielded distinct allele binding profiles for each epitope.  
 
 
 
 
2.5 Calculation of predicted population protection coverage 
Using the binding profile from 2.4 above, conserved epitopes were analysed for predicted 
population protection coverage (PPC) using the IEDB analysis tool, ( 
http://tools.iedb.org/tools/population/iedb_input). This covers 78 populations across 
multiple geographical areas (Bui et al., 2006). PPC quantifies the percentage of a given population 
likely to produce an immune response to an epitope. PPC values for sub-Saharan Africa and 
globally were estimated for both individual epitopes and epitope combinations.   
 
2.6 Generation of heteroclitic peptides and estimation their binding affinity and 
population coverage  
Heteroclitic peptides were generated by making 19 virtual single amino acid substitutions at 
each position of each epitope sequence, giving a set of 19 x l variants, where l is the epitope 
length. Each generated variant peptide was analysed using the same methodology as in 2.4 
and 2.5 above. The resulting predicted binding, allele binding profile, and PPC values were 
then compared to that of each progenitor epitope from which the heteroclitic variant set had 
been derived. This reduced the set of variant heteroclitic peptides to only those that had 
higher predicted affinity and higher predicted population coverage than the matrix/mother 
epitope.   
 
3 RESULTS 
 
3.1. CD8+ T cell epitope component 
We extracted 584 experimentally-confirmed CD8+ T cell epitopes from IEDB, deriving from 25 
separate antigens. CD8+ epitope frequency varied considerably between these antigens, 
resulting in a long-tail distribution. See Figure 1. Of the 25 IEDB epitope-bearing antigens, 8 
contained 10 or more epitopes, giving 518 epitopes in total. As detailed in Figure 2, we 
analysed these epitopes using 4 different approaches.  
First, for each of the 25 antigens, we created a separate multiple sequence alignment (MSA) 
comprising the 10 most similar but non-identical sequences found in the NCBI database. 
Variability analysis using the PVS server yielded 55 conserved epitopes deriving from 6 
antigens: TRAP (22 epitopes), CSP (13 epitopes), AMA-1 (8 epitopes), LSA-3 (7 epitopes), EXP-
1 (4 epitopes) and STARP (1 epitope). Second, we analysed the MSAs corresponding to the 8 
antigens bearing the highest number of epitopes. This yielded 47 conserved epitopes deriving 
from 4 proteins: TRAP (22 epitopes), CSP (13 epitopes), AMA-1(8 epitopes), and EXP-1(4 
epitopes).   
Third, we clustered at 90% similarity larger numbers of similar sequences corresponding to 
these 8 antigens. This yielded 34 conserved epitopes from the same 4 proteins.  Fourth, we 
repeated this process, again for the 8 antigens, but at 98% similarity. This yielded 28 
conserved epitopes, again from the same 4 proteins. Using the IEDB-binding prediction tool, 
HLA binding profiles were calculated for the 4 sets of epitopes, and the population coverage 
(PPC) calculated using the IEDB population-coverage tool. No peptide had a PPC greater than 
44.9%.  See Table 1. 
 
3.2. CD4+ T cell epitope component 
We extracted 483 experimentally-confirmed CD4+ T cell epitopes in IEDB, deriving from 25 
antigens. As detailed in Figure 3, we analysed CD4+ epitopes using 4 different approaches.  
First, for each of these 25 antigens, we created a separate MSA, comprising the 10 most 
similar but non-identical sequences found in the NCBI database. Variability analysis using the 
PVS server yielded 191 conserved CD4+ T cell epitope, deriving from 19 antigens.  Second, 
426 epitopes were collected from the 8 prioritised antigens shown in Figure 1. For 
consistency, we targeted these 8 due to the pre-eminence of CD8+ responses in protective 
immunity to malaria (Tsuji, 2010). Of the 426 epitopes, 153 were conserved and derived from 
7 antigens: MSP-1 (68 epitopes), CSP (40 epitopes), DNAJ (15 epitopes), AMA-1 (13 epitopes), 
MSP-2 (7 epitopes), TRAP (6 epitopes) and EXP-1 (4 epitopes).   
Third, for each of the 8 antigens, we clustered at 90% similarity larger numbers of similar 
sequences to generate a MSA. Variability analysis using PVS yielded 134 conserved CD4+ T 
cell epitopes. Fourth, we repeated clustering, again for the 8 antigens, but at 98% similarity. 
This yielded 106 conserved CD4+ T cell epitopes. Using the IEDB-binding prediction tool, HLA 
binding profiles were calculated for the 4 sets of epitopes detailed above, and the population 
coverage (PPC) calculated using the IEDB population-coverage tool. No peptide had a PPC 
greater than 78.9%. See Table 2. 
 
3.3. Selecting high population coverage epitope combinations  
For the 8 selected antigens, 8 CD8+ T cell epitopes (LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, 
TPYAGEPAPF, LLACAGLAY, LACAGLAYK, NEVVVKEEY and SLKKNSRSL) and 12 CD4+ epitopes 
(MRKLAILSVSSFLFV, SSVFNVVNSSIGLIM, KSKYKLATSVLAGLL, GLAYKFVVPGAATPY, 
AGLLGVVSTVLLGGV, KMEDYIKKNKTTIAN, DFNHYYTLKTGLEAD, HYYTLKTGLEADIKK, 
KYKIAGGIAGGLALL, KFSSSNNSVYNVQKL, DIEKKICKMEKCSSV, VKNVIGPFMKAVCVE) were 
common to the 3 data sets (10 most similar sequences, CD-Hit 90% and CD-Hit 98%). These 
provided a coherent basis for the construction of putative epitope ensemble vaccine designs. 
By the careful selection of conserved CD8+ and CD4+ epitopes it was possible to design a 
variety of different epitope collections, each with a combined PPC over 95%. See Table 3. 
By considering common conserved epitopes, with distinct HLA binding profiles, a putative 
optimal selection representing a minimally genetically-biased vaccine could be made: it 
comprised 7 CD8+ T cell epitopes (LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, TPYAGEPAPF, 
LLACAGLAY, NEVVVKEEY and SLKKNSRSL) and 3 CD4+ T cell epitopes (MRKLAILSVSSFLFV, 
KSKYKLATSVLAGLL and GLAYKFVVPGAATPY). This peptide set nominally covers 97.9% of the 
world population and over 85% of three African regions (East Africa: 88.2%; West Africa: 
90.2%; Central Africa 86.3%; South Africa: 73.8%).  
 
3.4. Selection of heteroclitic epitopes 
Following Theiler et al. (2016), we sought to broaden and deepen the potential scope and 
efficacy of this putative vaccine peptide set by adding heteroclitic epitopes to the candidate 
ensemble.  Heteroclitic peptides should be self-adjuvanting, mimic natural variation exhibited 
by pathogen subspecies, but remain immunologically representative of a target 
epitope(Adegoke and Grant, 2015). For each epitope, a series of heteroclitic peptides was 
generated systematically by making 19 single amino acid substitutions at each position of the 
epitope sequence. For SLKKNSRSL this corresponded to 171 variants (19 x l, where l is the 
peptide length) and for GLAYKFVVPGAATPY this generated 285 variants.  
After generating potential Heteroclitic epitopes, we assessed each variant for predicted 
binding affinity and calculated PPC. For example, LLMDCSGSI had 16 point-mutations with 
larger PPC values: the highest being the LLMDHSGSI epitope (60.0%); while the 
MRKLAILSASSFLFV variant bound 22 HLA molecules, allowing a single heteroclitic peptide to 
cover 81.8% of the world population. Heteroclitic epitopes had higher PPC values for all 
epitopes, except TPYAGEPAP and NEVVVKEEY. See Table 4.  
After assessment of binding profile and PPC of individual heteroclitic peptides, we then 
selected heteroclitic peptides for inclusion in proposed epitope ensemble vaccines. Addition 
of the heteroclitic peptide TFYAGEPAPF to the ensemble for example alone raised its world 
PPC to 98.8% and raised coverage in all four African regions over 80%. See Table 5.  Adding 
FAIFFDLFLV (an analogue of FLIFFDLFLV mutated at position 2), MLACAGLAYK (an analogue of 
LLACAGLAYK mutated at position 1), TFYAGEPAPF (an analogue of TPYAGEPAPF mutated at 
position 2), and RLACAGLAY (an analogue of LLACAGLAY mutated at position 1) to our best 
combination, formed a final 14 epitope ensemble. The addition of heteroclitic peptides to this 
epitope combination raised the world PPC to 99.2%, East Africa to 94.6%, West Africa to 
96.5%, Central Africa to 92.6%, and South Africa to 90.9%.  
 
 
5 DISCUSSION 
 
In the context of a worldwide vaccination programme, a broadly protective anti-malaria 
vaccine would assist malaria eradication both globally and in endemic areas. Natural human 
acquired immunity can generate antibodies against the blood stage antigens while 
immunisation with irradiated sporozoites can generate a cellular response preventing 
hepatocyte invasion (Doolan et al., 2014). Major challenges remain however, such as the 
multifactorial nature of protective immunity, the many epitopes recognised by the immune 
system, antigenic variation, and MHC allelic diversity. Subunit vaccines based on a single 
antigen may evoke too narrow an immune response and lack protection in genetically diverse 
populations. Thus it is important to prioritize both antigens and epitopes for vaccine design 
(Diez-Rivero and Reche, 2012; Molero-Abraham et al., 2015). The WHO has a strategic goal of 
developing a second-generation malaria vaccine with 75% or more efficacy by 2030 (WHO, 
2016). An effective vaccine would likely include antigenic determinants inducing protective 
immunity not achieved naturally or following immunisation with an irradiated sporozoite. 
Here, we sought to identify highly conserved epitopes that could form the basis of a putative 
epitope ensemble vaccine against malaria, with a target population coverage of 95%.  
One example of an epitope-based malaria vaccine - RTS,S - already exists. RTS,S is constructed 
from part of the CSP repeated region and C terminal region known to contain T cell epitopes 
(Cohen et al., 2010). Specifically, RTS include one conserved CD4+ T cell epitope and two 
polymorphic CD4+ and CD8+ T cell epitopes (Crompton et al., 2010). Although RTS,S 
demonstrates the feasibility of an epitope ensemble vaccine targeting malaria, in clinical trials 
following patients over 7 years, the efficacy of RTS,S is not maintained, being almost zero by 
the fourth year (Olotu et al., 2016). Our proposed epitope ensemble vaccine contains both 
conserved CD8+ and CD4+ T cell epitopes from 8 P. falciparum antigens with 95% population 
coverage. 
In our designed putative vaccine, two epitopes were part of the CSP protein, expressed in 
large quantities by sporozoites (Florens et al., 2002), six were derived from the 
thrombospondin-related anonymous protein (TRAP), also known as sporozoite surface 
protein 2 (SSP2). CSP and TRAP/SSP2 immunogenicity has been demonstrated previously and 
it has been suggested that joint immunisation with both TRAP and CSP could be more 
efficacious than separate vaccines (Hodgson et al., 2015). Finally, our proposed peptide set 
contains epitopes from AMA-1 and EXP-1, as well as CSP and TRAP.  A multi-epitope vaccine 
targeting many antigens should induce a more robust immune response. Doolan et al. (2003) 
have shown that irradiated sporozoite-induced protective immunity following immunisation 
is dispersed over a large number of antigens. While previous studies show that sustained 
complete protection may be induced by irradiated sporozoites, no current vaccine yields such 
sustained immunity. 
Nine of ten epitopes in our final ensemble were associated with the pre-erythrocytic (hepatic) 
stage antigens; and it is this stage which will induce cell-mediated responses. Many studies 
have shown hepatic stage antigens to induce CD8+ T cell response correlated to sterile 
protection (Ewer et al., 2013). One MHC-I epitope included in our epitope ensemble vaccine 
was derived from the AMA-1 antigen expressed in both pre-erythrocytic and erythrocytic 
stages. This AMA-1 derived epitope - NEVVVKEEY - shows binding affinity to the HLA-B44 
molecule. No epitope in our final ensemble was derived from sexual stage antigens, since 
vaccines targeting sexual stage antigens are mainly mediated by antibodies. 
Our final combination contains both CD8+ and CD4+ epitopes. All of the CD4+ epitopes were 
also independently reported by Doolan et al. (2000) as experimentally-confirmed, highly-
conserved, cross-reactive T cell epitopes. All epitopes bound extensively to the most 
prevalent DRB1 alleles, and gave good recall of lymphoproliferative and cytokine (IFN-γ and 
IL-10) responses in Kenyan residents and irradiated sporozoite-immunised individuals. Doolan 
et al. (2000) estimated population coverage of these epitopes in five ethnicities (Caucasian, 
Hispanic, North American Black, Japanese and Chinese) with a higher minimum coverage of 
(72.0%) compared to the current study (60.3%). Eight conserved CD8+ epitopes showed 
binding affinities to four HLA-A alleles (A*01, A*02, A*03 and A*11) and seven HLA-B alleles 
(B*07, B*08, B*15, B*35, B*44 and B*53). Combining these epitopes provide a universal PPC 
value of 88.4%. According to Sette and Sidney (1999), epitopes binding to six HLA I allele 
super-types (A*01, A*02, A*03, B*07, A*24, and B*44) are needed to cover 99.3% of the 
world population. Thus, a CD8+ epitope that binds to HLA-A*24 is required to achieve optimal 
coverage. 
Peptide-based vaccines have several advantages, including safety, the possibility of modifying 
peptide sequences to improve immunogenicity, and the ability to obtain focused immune 
responses for selected antigens(Purcell et al., 2007). Prior to this, exploratory work is also 
needed on the best means to deliver the set of peptides, whether as a cocktail of peptide 
fragments, a single polypeptide, as part of an expression vector-based vaccine, as part of a 
DNA vaccine, or as part of a fusion vaccine with a carrier virus. 
One of the significant advances over our previous work (Molero-Abraham et al., 2013; Sheikh 
et al., 2016) is the addition of carefully selected heteroclitic peptides. A well-known drawback 
of epitope ensemble vaccines is poor immunogenicity, usually necessitating the use of 
suitable adjuvants (Bayry et al., 2009). In this context, adding heteroclitic peptides should 
foment self-adjuvanting effects by augmenting the immune responses of individual epitopes 
and of the ensemble as a whole. For example, in the immunotherapy of human HIV, where 
heteroclitic peptides can raise CD8+ T cell proliferation by 20% relative to reference peptides 
(Adegoke et al., 2015). Adding variant sequences close to those of recognition epitopes is also 
known experimentally to broaden the breadth and depth of vaccine immune response in 
animal models (Abdul-Jawad et al., 2016; Barouch et al., 2010; Santra et al., 2010). Thus, the 
capacity of a heteroclitic peptide to enhance T cell function has important implications for 
chronic infection, where T cell exhaustion is more likely. Moreover, heteroclitic peptides bind 
to additional HLA molecules providing higher population coverage compared to native 
epitopes.  
In our designed putative vaccine, single amino acid substitutions increased the population 
coverage by 1.6% to 12.1% for a single peptide. Thus, combining several variant peptides with 
core epitopes increases overall coverage to above 99%. Several heteroclitic peptides bind to 
HLA-A*30 and HLA-A*23, which are frequent alleles in African populations, and thus allow 
coverage to rise over 90% for African regions.  
However, individual and combined epitopes provided lower coverage of Africa compared to 
the global population. The epitope TPYAGEPAPF binds to the HLA-B allele (B*53:01), which is 
common in the West African population (Spinola et al., 2011). Importantly, HLA-B*53 has 
been associated with the reduction in life-threatening malaria (Hill et al., 1991). Moreover, 
other epitopes did not bind to alleles with high frequencies in African regions. Thus, to reach 
nearly 95% coverage, other epitopes restricted by the prevalent super-types (HLA-A*23, HLA-
A*30, HLA-B*58, and HLA-C*06) were required (Peterson et al., 2014; Spinola et al., 2011).  In 
TPYAGEPAPF, substitution of proline (P) with phenylalanine (F) resulted in TFYAGEPAPF, 
which is restricted by HLA-A*23. Addition of this heteroclitic epitope to our vaccine ensemble 
provides higher coverage in Africa. MHC-II epitopes bind to many prevalent alleles in Africa, 
such as DRB3*02:02:01, DRB1*11:01:02, DRB4* 01:01:01, DRB5*01:01:01. Combination of 
MHC-II epitopes failed to reach 95% coverage for African regions. Other epitopes restricted 
to allelic supertypes including DQA1*01:02:01, DQB1*03:01:01, DPA1*01:03:01, and 
DPB1*01:01:01 (Peterson et al., 2014) would be necessary to immunise most subpopulations 
in Africa.  
 
 
6 Conclusion 
 
Leveraging comparative sequence analysis, we have used immunoinformatics to select an 
optimal set of experimentally-tested epitopes known to be immunogenic as a designed 
genetically-unbiased pre-validated epitope-based synthetic malaria vaccine. We selected an 
epitope set comprising LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, TPYAGEPAPF, LLACAGLAY, 
NEVVVKEEY, SLKKNSRSL, MRKLAILSVSSFLFV, KSKYKLATSVLAGLL and GLAYKFVVPGAATPY as 
the best candidate for a multi-epitope vaccine targeting malaria. Together, these epitopes are 
predicted to provide high universal coverage (97.9%). Both HLA class I and II epitopes are 
required for a broadly effective malaria vaccine. Our proposed epitope combination included 
4 heteroclitic peptides selected for having increased HLA presentation profiles. Targeting a 
specific population is more difficult, highlighting the role that heteroclitic peptides might play 
in achieving high subpopulation coverage. Heteroclitic peptides with single amino acids 
substitution have different HLA binding profiles, raising the overall population coverage of 
our ensemble. In-vitro and in vivo testing of our ensemble vaccine for protective immune 
responses is now needed, including a thorough evaluation of peptide properties (such as 
solubility), their toxicity, heteroclitic peptides immunogenicity, and a rigorous examination of 
their efficacy against malaria. 
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FIGURE 1.  
CD8+ Epitope Frequency among P. falciparum Antigens 
P. falciparum proteins containing 1 or more CD8+ epitopes, sorted by prevalence. CSP: 
Circumsporozoite protein (Hodgson et al., 2015) , UniProt: P08307, CSP_PLAFW. MSP: Merozoite 
surface protein (Ahouidi et al., 2016), UniProt: P04933, MSP1_PLAFW. SSP2/TRAP: Sporozoite surface 
protein 2/Thrombospondin-related anonymous protein (John et al., 2003), UniProt: Q9GTW7, 
Q9GTW7_PLAFA. AMA-1: Apical membrane antigen 1 (Schussek et al., 2013), UniProt: Q94661, 
Q94661_PLAFA. Pf332: P. falciparum antigen 332, DBL-like protein (Nilsson et al., 2011), UniProt: 
Q7JPX6, Q7JPX6_PLAFA. EXP-1: Exported protein-1/Circumsporozoite-related antigen (John et al., 
2003), UniProt: Q548U2, Q548U2_PLAFA. SERA: Serine-repeat antigen (Owalla et al., 2013) UniProt: 
Q9TY95, SERA_PLAF7. Pfg27/25: P. falciparum gamete antigen 27/25 (Read et al., 1994), UniProt: 
Q8IEU2, Q8IEU2_PLAF7. P101: 101 kDa malaria antigen (Vargas-Serrato et al., 2002), UniProt: Q8I5D2, 
ABRA_PLAF7. PfHsp70: P. falciparum Heat shock 70 kDa protein (Pooe et al., 2017), UniProt: P11144, 
HSP70_PLAFA. LSA: Liver stage antigen (Ferraro et al., 2013), UniProt: Q25893, Q25893_PLAFA. 
EBA175: Erythrocyte binding antigen175 kDa (Okenu et al., 2000), UniProt: Q95VT1, Q95VT1_PLAFA. 
CARP: Clustered-asparagine-rich protein (Wahlgren et al., 1991), UniProt: P13824, ARP2_PLAFA. 
KAHRP: Knob-associated histidine-rich protein (Weng et al., 2014), UniProt: P13817, KNOB_PLAFA. 41 
kDa antigen: Fructose-bisphosphate aldolase (Kim et al., 1998), UniProt: P14223, ALF_PLAFA. RAP: 
Rhoptry-associated protein (Ghosh et al., 2017), UniProt: Q25730, Q25730_PLAFA. STRAP: Sporozoite 
threonine-asparagine-rich protein (Suwancharoen et al., 2011), UniProt: B0Z8E6, B0Z8E6_PLAFA. 
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FIGURE 2. 
CD8 T cell Epitope selection overview.  
The figures compares number of HLA I epitopes that were obtained from the primary results (in Red 
boxes) and epitopes after clustering protein sequences with the CD-Hit tool (in Blue boxes). (A) The 
number of conserved HLA I epitopes from all analysed sets. (B) The number of epitopes that show 
binding affinity toward HLA class I molecules. 
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FIGURE 3. 
CD4 T cell Epitope selection overview  
This figure compares the number of HLA II epitopes obtained from the primary results (Red boxes) 
and epitopes after clustering protein sequences with the CD-Hit tool (Blue boxes). (A) The number of 
conserved HLA II epitopes from all analysed sets. (B) The number of epitopes that show affinity toward 
HLA II molecules. 
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TABLE 1.  
Conserved CD8+ T cell epitopes from P. falciparum 
 
Projected population coverage (PPC) values of conserved class I epitopes. PPC quantifies the 
percentage of a given population group who are estimated to produce some immune response to that 
antigen. The 14 epitopes shown were derived from both the 25 and 8 antigen sets. The eight epitopes 
also present in the CD-HIT clustering are shown in bold.  
* Average coverage for East, West, South, and Central Africa.   
 HLA class I epitopes Antigen HLA I binding profile 
% PPC 
World Africa* 
1 LLMDCSGSI TRAP 
A*02:01, A*02:03, 
B*15:01 
44.92 10.71 
2 FLIFFDLFLV TRAP 
A*02:01, A*02:03, 
A*02:06 
41.35 10.05 
3 ALFFIIFNK EXP-1 
A*03:01, A*11:01, 
A*31:01, A*68:01 
40.03 9.85 
4 LLACAGLAYK TRAP A*03:01, A*11:01 30.92 5.91 
5 TPYAGEPAPF TRAP 
B*07:02, B*35:01, 
B*51:01, B*53:01 
29.39 24.00 
6 LLACAGLAY TRAP A*01:01, B*15:01, 24.32 4.96 
7 FEFTYMINF AMA-1 
B*40:01, B*44:02, 
B*44:03 
20.88 5.38 
8 LACAGLAYK TRAP A*11:01 15.53 1.18 
9 NEVVVKEEY AMA-1 B*00:44, B*44:03 13.63 4.85 
10 KSHGKGYNW AMA-1 
A*32:01, B*57:01, 
B*58:01, 
11.53 7.70 
11 KNKEKALI TRAP B*08:01 10.55 4.64 
12 SLKKNSRSL CSP B*08:01 10.55 4.64 
13 YKSHGKGYNW AMA-1 -10:8:4B  3.42 5.18 
14 GLIMVLSFL CSP A*02:03 0.97 0.08 
TABLE 2.  
Conserved CD4 T cell epitopes from P. falciparum  
 HLA II epitopes Antigen HLA II binding profile % PPC 
world 
% PPC 
Africa* 
1 MRKLAILSVSSFLFV CSP 
DRB1*01:01, DRB1*03:01 
DRB1*04:01, DRB1*04:05 
DRB1*07:01, DRB1*08:02 
DRB1*12:01, DRB1*13:02 
DRB1*11:01, DRB1*15:01 
DRB4*01:01, DRB5*01:01 
DPA1*01:03/DPB1*02:01 
DPA1*01/DPB1*04:01 
DPA1*02:01/DPB1*01:01 
DPA1*02:01/DPB1*05:01 
DPA1*02:01/DPB1*14:01 
DPA1*03:01/DPB1*04:02 
78.93 31.75 
2 SSVFNVVNSSIGLIM CSP 
DRB1*03:01, DRB1*04:01 
DRB1*04:05, DRB1*07:01 
DRB1*08:02, DRB1*09:01 
DRB1*11:01, DRB1*13:02 
DRB1*15:01, DRB3*02:02 
DRB5*01:01 
74.13 30.27 
3 SLRWIFKHVAKTHLK DNAJ 
DRB1*03:01, DRB1*04:01 
DRB1*04:05, DRB1*07:01 
DRB1*08:02, DRB1*09:01 
DRB1*11:01, DRB1*12:01 
DRB1*15:01, DRB3*02:02 
DRB4*01:01, DRB5*01:01 
72.96 27.90 
4 NFFIFVTFNIKNESK MSP-2 
DRB1*03:01, DRB1*04:01 
DRB1*04:05, DRB1*07:01 
DRB1*08:02, DRB1*11:01 
DRB1*12:01, DRB1*15:01 
DRB3*01:01, DRB5*01:01 
DPA1*01/DPB1*04:01 
DPA1*01:03/DPB1*02:01 
DPA1*02:01/DPB1*01:01 
DPA1*03:01/DPB1*04:02 
DPA1*02:01/DPB1*05:01 
DPA1*02:01/DPB1*14:01 
69.47 26.00 
5 KSKYKLATSVLAGLL EXP-1 
DRB1*01:01, DRB1*04:01 
DRB1*04:05, DRB1*07:01 
DRB1*08:02, DRB1*09:01 
DRB1*11:01, DRB1*15:01 
DRB3*02:02, DRB5*01:01 
DPA1*01/DPB1*04:01 
DPA1*02:01/DPB1*01:01 
DPA1*02:01/DPB1*05:01 
DPA1*02:01/DPB1*14:01 
66.73 20.25 
DPA1*03:01/DPB1*04:02 
DQA1*01:02/DQB1*06:02 
6 GLAYKFVVPGAATPY TRAP 
DRB1*01:01, DRB1*03:01 
DRB1*07:01, DRB1*08:02 
DRB1*09:01, DRB1*11:01 
DRB1*12:01, DRB5*01:01 
DQA1*05:01/DQB1*03:01 
60.28 27.05 
7 LLSAFEFTYMINFGR AMA-1 
DRB1*04:01, DRB1*04:05 
DRB1*07:01, DRB1*11:01 
DRB1*15:01, DRB3*01:01 
DRB5*01:01 
DPA1*01:03/DPB1*02:01 
DPA1*01/DPB1*04:01 
DPA1*02:01/DPB1*01:01 
DPA1*02:01/DPB1*05:01 
DPA1*02:01/DPB1*14:01 
DPA1*03:01/DPB1*04:02 
DQA1*01:01/DQB1*05:01 
53.70 16.83 
8 AGLLGVVSTVLLGGV EXP-1 
DRB1*03:01, DRB1*04:01 
DRB1*04:05, DRB1*11:01 
DRB1*15:01, DRB5*01:01 
53.40 17.45 
9 KMEDYIKKNKTTIAN MSP-1 
DRB1*08:02, DRB1*09:01 
DRB1*13:02, DRB1*04:01 
DRB1*03:01, DRB1*11:01 
DRB4*01:01 
48.70 23.39 
10 LKKLSSIMERYAGGK DNAJ 
DRB1*04:05, DRB1*08:02 
DRB1*11:01, DRB1*04:01 
DRB1*15:01, DRB1*09:01 
DRB5*01:01 
46.43 12.68 
11 YKAYVSYKKRKAQEK P101 
DRB1*04:01, DRB1*08:02, 
DRB1*09:01, DRB1*11:01, 
DRB1*15:01, DRB3*02:02 
DRB5*01:01, 
44.18 11.29 
12 GDIIKKMQTLWDEIM DNAJ 
DRB1*03:01, DRB1*04:01 
DRB1*04:05, DRB1*08:02 
DRB1*11:01, DRB3*01:01 
DRB4*01:01 
DQA1*01:01/DQB1*05:01 
41.08 17.03 
13 LTGYSLFQKEKMVLN MSP-1 
DRB1*03:01, DRB1*04:01 
DRB1*08:02, DRB1*11:01 
DRB5*01:01 
DPA1*01/DPB1*04:01 
DPA1*01:03/DPB1*02:01 
DPA1*02:01/DPB1*01:01 
DPA1*02:01/DPB1*05:01 
DPA1*02:01/DPB1*14:01 
38.72 15.64 
14 DFNHYYTLKTGLEAD MSP-1 
DRB1*04:01, DRB1*04:05 
DRB1*09:01, DRB1*11:01 
DRB5*01:01 
29.38 11.99 
  
Projected population coverage (PPC) values of conserved HLA II-restricted epitopes. PPC quantifies 
the percentage of a given population group who are estimated to produce some immune response to 
that antigen. All 28 epitopes were derived from the set contained 25 antigens. 23 epitopes were 
derived from the set of 8 selected antigens; epitopes 11, 18, 22, 24 and 28 were derived from proteins 
other than the eight selected antigens. Epitopes shown in bold are also common to the CD-HIT 
clustered data. * Average coverage for East, West, South, and Central Africa. 
 
  
15 IRANELDVLKKLVFG MSP-1 
DRB1*03:01, DRB1*11:01 
DPA1*03:01/DPB1*04:02 
DQA1*01:01/DQB1*05:01 
27.37 15.09 
16 HYYTLKTGLEADIKK MSP-1 
DRB1*04:05, DRB1*08:02 
DRB1*09:01, DRB1*11:01 
21.43 11.64 
17 KYKIAGGIAGGLALL TRAP 
DRB1*09:01, DRB1*11:01 
DRB5*01:01 
DQA1*05:01/DQB1*03:01 
16.59 10.11 
18 
GSSPMEFLQIIEDYG 
 
SERA 
DRB1*04:05, DRB4*01:01, 
DRB1*11:01 
DQA1*03:01/DQB1*03:02, 
DQA1*04:01/DQB1*04:02, 
DQA1*05:01/DQB1*02:01, 
13.39 9.21 
19 KFSSSNNSVYNVQKL MSP-1 DRB1*04:01 11.21 0.54 
20 IQNSLSTEWSPCSVT CSP DRB1*04:01 11.21 0.54 
21 DIEKKICKMEKCSSV CSP DRB1*11:01 10.54 7.70 
22 SNYPYNYVKVGEQCP SERA DRB1*11:01, DRB5*01:01 10.54 7.70 
23 VKNVIGPFMKAVCVE TRAP DRB1*08:02 2.33 0.12 
24 NNFMNRNMKNKNMNN CARP DRB5*01:01, DRB1*08:02 2.33 0.12 
25 KLQKTYSQYKVQYDM DNAJ DRB1*04:05, DRB5*01:01 3.02 1.68 
26 EEHVEEPASDVQQTS DNAJ DQA1*04:01/DQB1*04:02 0.00 0.00 
27 MQTLWDEIMDINKRK DNAJ 
DRB3*01:01, DRB5*01:01, 
DQA1*01:01/DQB1*05:01 
0.00 0.00 
28 WMNLWDNGKILHNKN SERA DRB3*01:01 0.00 0.00 
TABLE 3.  
Constituents of proposed minimal malaria Epitope Ensemble vaccines  
 
Epitope Combination 
% PPC 
World 
East 
Africa 
West  
Africa 
Central 
Africa 
South 
Africa 
 
LLMDCSGSI, ALFFIIFNK 
TPYAGEPAPF, 
MRKLAILSVSSFLFV 
95.95 83.93 86.56 82.99 62.64 
 
FLIFFDLFLV, LLACAGLAY,  
LLACAGLAYK, 
MRKLAILSVSSFLFV 
KSKYKLATSVLAGLL 
95.73 80.63 78.95 73.93 55.71 
 
FLIFFDLFLV, LLACAGLAY 
LLACAGLAYK, 
MRKLAILSVSSFLFV 
SSVFNVVNSSIGLIM 
95.73 80.63 78.95 73.93 55.71 
 
FLIFFDLFLV, LLACAGLAY,   
LLACAGLAYK, 
GLAYKFVVPGAATPY  
SSVFNVVNSSIGLIM 
95.73 80.63 78.95% 73.93 55.71 
 
FLIFFDLFLV, LLACAGLAY,   
LLACAGLAYK, 
SSVFNVVNSSIGLIM  
KSKYKLATSVLAGLL 
95.27 76.88 78.06 70.68 55.71 
 
LLMDCSGSI, LLACAGLAYK 
TPYAGEPAPF, 
MRKLAILSVSSFLFV 
95.07 82.98 84.74 82.04 56.66 
 
FLIFFDLFLV, LLACAGLAYK 
LLACAGLAY, MRKLAILSVSSFLFV 
95.6 79.58 75.20 73.03 54.74 
 FLIFFDLFLV, LLACAGLAY 
LLACAGLAYK, 
KSKYKLATSVLAGLL 
GLAYKFVVPGAATPY 
95.02 75.82 74.16 65.08 52.43 
 
Composition of peptide sets corresponding to proposed epitope ensemble vaccines. A summary of 
the combination of epitopes (HLA I and HLA II epitopes) that were derived from the 8 selected 
antigens, able to achieve over 95% world population coverage.  
  
TABLE 4. 
Comparison of the binding profile and calculated PPC of heteroclitic peptides versus those of the 
original progenitor epitope.  
 
Core peptide HLA-profile  % PPC Heteroclitic 
peptide 
HLA binding 
profile 
% PPC 
LLMDCSGSI 
A*02:01, 
A*02:03, 
B*15:01 
 
44.92 MLMDCSGSI 
A*02:01, 
A*02:03, 
A*02:06, 
B*15:01, 
46.30 
FLIFFDLFLV 
A*02:01, 
A*02:03, 
A*02:06 
41.3 FAIFFDLFLV 
A*02:01, 
A*02:06, 
A*68:02, 
B*51:01 
46.80 
LLACAGLAYK 
A*03:01, 
A*11:01 
30.92 MLACAGLAYK 
A*03:01, 
A*68:01, 
A*11:01 
35.75 
TPYAGEPAPF 
B*07:02, 
B*35:01, 
B*51:01, 
B*53:01 
29.39 TFYAGEPAPF 
A*23:01, 
A*24:02 
26.18 
LLACAGLAY 
A*01:01, 
B*15:01, 
24.32 
RLACAGLAY 
 
B*15:01, 
A*03:01, 
A*30:02 
25.87 
SLKKNSRSL B*08:01 10.55 
RLKKNSRSL 
 
B*08:01, 
B*07:02 
22.61 
MRKLAILSVSS
FLFV 
 
DRB1*01:01, 
DRB1*03:01, 
DRB1*04:01, 
DRB1*04:05, 
DRB1*07:01, 
DRB1*08:02, 
DRB1*12:01, 
DRB1*13:02, 
DRB1*11:01, 
DRB1*15:01, 
DRB4*01:01, 
DRB5*01:01, 
DPA1*01:03/D
PB1*02:01, 
DPA1*01/DPB1
*04:01, 
78.93 
MRKLAILSASS
FLFV 
DRB1*04:01, 
DRB1*15:01, 
DRB1*01:01, 
DRB1*03:01, 
DRB1*12:01, 
DRB4*01:01, 
DRB1*04:05, 
DRB5*01:01, 
DRB1*07:01, 
DRB3*02:02, 
DRB1*09:01, 
DRB1*13:02, 
DRB3*01:01, 
DPA1*01:03/DP
B1*02:01, 
DPA1*01/DPB1
81.81 
DPA1*02:01/D
PB1*01:01, 
DPA1*02:01/D
PB1*05:01, 
DPA1*02:01/D
PB1*14:01, 
DPA1*03:01/D
PB1*04:02 
*04:01, 
DRB1*11:01, 
DPA1*02:01/DP
B1*01:01, 
DRB1*08:02, 
DPA1*02:01/DP
B1*14:01, 
DQA1*01:02/D
QB1*06:02, 
DPA1*02:01/DP
B1*05:01, 
DPA1*03:01/DP
B1*04:02 
KSKYKLATSV
LAGLL 
 
 
 
 
 
DRB1*01:01, 
DRB1*04:01, 
DRB1*04:05, 
DRB1*07:01, 
DRB1*08:02, 
DRB1*09:01, 
DRB1*11:01, 
DRB1*15:01, 
DRB3*02:02, 
DRB5*01:01, 
DPA1*01/DPB1
*04:01, 
DPA1*02:01/D
PB1*01:01, 
DPA1*02:01/D
PB1*05:01, 
DPA1*02:01/D
PB1*14:01, 
DPA1*03:01/D
PB1*04:02, 
DQA1*01:02/D
QB1*06:02 
66.73 
KIKYKLATSVL
AGLL 
DRB1*09:01, 
DRB3*02:02, 
DRB1*01:01, 
DRB1*04:01, 
DPA1*02:01/DP
B1*14:01, 
DRB1*08:02, 
DRB1*11:01, 
DRB1*04:05, 
DRB1*07:01, 
DPA1*03:01/DP
B1*04:02, 
DQA1*01:02/D
QB1*06:02, 
DPA1*01/DPB1
*04:01, 
DRB5*01:01, 
DPA1*02:01/DP
B1*01:01, 
DRB1*12:01, 
DRB1*15:01, 
DRB4*01:01, 
DRB1*13:02, 
DPA1*02:01/DP
B1*05:01 
72.95 
GLAYKFVVPG
AATPY 
DRB1*01:01, 
DRB1*03:01, 
DRB1*07:01, 
DRB1*08:02, 
DRB1*09:01, 
DRB1*11:01, 
DRB1*12:01, 
DRB5*01:01, 
DQA1*05:01/D
QB1*03:01 
60.28 
GLRYKFVVPG
AATPY 
DRB1*09:01, 
DRB5*01:01, 
DRB1*01:01, 
DRB1*11:01, 
DQA1*05:01/D
QB1*03:01, 
DRB1*08:02, 
DRB1*12:01, 
DRB1*04:01, 
DRB1*07:01, 
DRB1*03:01 
67.23 
  
Comparison of native epitopes to heteroclitic variants, illustrating their PPC values. 
Substitution site are highlighted and underlined. Heteroclitic peptides have larger PPC values 
compared with core epitopes except TPYAGEPAP epitope. All possible mutations within 
NEVVVKEEY epitope show neither higher PPC value nor distinct HLA binding profile.  
  
 TABLE 5 
Final proposed malaria epitope ensemble vaccine including one or several heteroclitic 
peptides.  
 
Epitope combination 
World 
%PPC 
East 
Africa 
%PPC 
West 
Africa 
%PPC 
Central 
Africa 
%PPC 
South 
Africa 
%PPC 
LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, 
TPYAGEPAPF, LLACAGLAY, 
NEVVVKEEY, SLKKNSRSL, 
MRKLAILSVSSFLFV, KSKYKLATSVLAGLL, 
GLAYKFVVPGAATPY 
97.89 88.15 90.23 86.31 73.83 
LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, 
TPYAGEPAPF, LLACAGLAY, 
NEVVVKEEY, SLKKNSRSL, 
MRKLAILSVSSFLFV, KSKYKLATSVLAGLL, 
GLAYKFVVPGAATPY, TFYAGEPAPF 
98.90 90.69 94.06 89.51 81.94 
LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, 
TPYAGEPAPF, LLACAGLAY, 
NEVVVKEEY, SLKKNSRSL, 
MRKLAILSVSSFLFV, KSKYKLATSVLAGLL, 
GLAYKFVVPGAATPY, MLACAGLAYK 
98.13 88.55 91.26 86.86 76.35 
LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, 
TPYAGEPAPF, LLACAGLAY, 
NEVVVKEEY, SLKKNSRSL, 
MRKLAILSVSSFLFV, KSKYKLATSVLAGLL, 
GLAYKFVVPGAATPY, FAIFFDLFLV 
98.00 90.39 90.92 87.68 78.81 
LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, 
TPYAGEPAPF, LLACAGLAY, 
NEVVVKEEY, SLKKNSRSL, 
MRKLAILSVSSFLFV, KSKYKLATSVLAGLL, 
GLAYKFVVPGAATPY, RLACAGLAY 
97.99 90.24 91.86 88.07 78.31 
LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, 
TPYAGEPAPF, LLACAGLAY, 
NEVVVKEEY, SLKKNSRSL, 
MRKLAILSVSSFLFV, KSKYKLATSVLAGLL, 
GLAYKFVVPGAATPY, MLMDCSGSI 
97.89 88.15 90.23 86.31 73.83 
LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, 
TPYAGEPAPF,  LLACAGLAY, 
NEVVVKEEY, SLKKNSRSL, 
MRKLAILSVSSFLFV, KSKYKLATSVLAGLL, 
GLAYKFVVPGAATPY, RLKKNSRSL 
97.89 88.15 90.23 86.31 73.83 
LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, 
TPYAGEPAPF, LLACAGLAY, 
NEVVVKEEY, SLKKNSRSL, 
MRKLAILSVSSFLFV, KSKYKLATSVLAGLL, 
GLAYKFVVPGAATPY, 
MRKLAILSASSFLFV 
97.89 88.15 90.23 86.31 73.83 
LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, 
TPYAGEPAPF, LLACAGLAY, 
NEVVVKEEY, SLKKNSRSL, 
MRKLAILSVSSFLFV, KSKYKLATSVLAGLL, 
GLAYKFVVPGAATPY, 
KIKYKLATSVLAGLL 
97.89 88.15 90.23 86.31 73.83 
LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, 
TPYAGEPAPF, LLACAGLAY, 
NEVVVKEEY, SLKKNSRSL, 
MRKLAILSVSSFLFV, KSKYKLATSVLAGLL, 
GLAYKFVVPGAATPY, 
GLRYKFVVPGAATPY 
97.89 88.15 90.23 86.31 
73.83 
 
LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, 
TPYAGEPAPF, LLACAGLAY, 
NEVVVKEEY,  SLKKNSRSL, 
MRKLAILSVSSFLFV, KSKYKLATSVLAGLL, 
GLAYKFVVPGAATPY, FAIFFDLFLV, 
TFYAGEPAPF 
98.98 92.66 94.60 90.71 86.03 
LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, 
TPYAGEPAPF, LLACAGLAY, 
NEVVVKEEY, SLKKNSRSL, 
MRKLAILSVSSFLFV, KSKYKLATSVLAGLL, 
GLAYKFVVPGAATPY, FAIFFDLFLV, 
TFYAGEPAPF, RLACAGLAY 
99.05 94.28 95.79 92.15 89.25 
LLMDCSGSI, FLIFFDLFLV, LLACAGLAYK, 
TPYAGEPAPF, LLACAGLAY, 
NEVVVKEEY, SLKKNSRSL, 
MRKLAILSVSSFLFV, KSKYKLATSVLAGLL, 
GLAYKFVVPGAATPY, FAIFFDLFLV, 
MLACAGLAYK, TFYAGEPAPF, 
RLACAGLAY 
99.21 94.55 96.46 92.56 90.85 
 
 The combination of suggested vaccine candidates with single or multiple heteroclitic peptides 
(underlined in bold) as identified in Table 4, including the original optimal epitope ensemble 
for comparison. A minimum of four heteroclitic peptides are required to achieve >90% for all 
African regions. 
